investigators – Page 7 – Communicable Diseases Research

A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients – a structured summary of a study protocol for a randomized controlled trial

증상이 있는 COVID 19 환자의 관리에서 표준 동종 요법 치료와 함께 Siddha 의약품, Kaba Sura Kudineer(KSK) 및 Nilavembu Kudineer(NVK)의 효과를 평가하기 위한 이중 맹검 위약 대조 비교 임상 시험 - 에 대한 연구 프로토콜의 구조화된 요약 무작위 대조 시험

Letter

Published on 2021-02-112022-09-10
Journal: Trials [Category] MERS, 임상,

Bringing evidence from press release to the clinic in the era of COVID-19

코로나19 시대, 언론보도부터 진료소까지 증거자료 제공

Review

Published on 2021-02-112022-09-11
Journal: Journal of Antimicrobial Chemotherapy [Category] 임상,

A quadruple blinded placebo controlled randomised trial to evaluate the effectiveness of an Iodine complex for patients with mild to moderate COVID-19 in Pakistan (I-COVID-PK): A structured summary of a study protocol for a randomised controlled trial

파키스탄에서 경증에서 중등도의 COVID-19 환자에 대한 요오드 복합체의 효과를 평가하기 위한 4중 맹검 위약 대조 무작위 시험(I-COVID-PK): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-02-102022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 30-Day mortality Admission age alleviation alleviation of symptom approved Arm ARMS baseline blinded Blinding calculated Care care providers Chest chest scan Chronic illness clinic clinical Clinical improvement Clinical management co-morbidities co-morbidity comparator complex coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 adult patient COVID-19 adult patients Disinfection dissemination doctor Effectiveness Efficacy element enrolled evaluate excluded four group four groups Gender groups HRCT Infection information initial initial symptom initial symptoms Intention investigator investigators Iodine IRB lung involvement management guidelines Mild mild to moderate mild to moderate disease Moderate COVID-19 moderate disease morbidities National Health Service National Health Services non-pregnant females number objective outcome Pakistan participant Participants Patient patients PCR Placebo placebo-controlled Polymer positive Primary outcomes protocol radiological radiological improvement randomised randomised controlled trial Randomised trial randomization Randomized receiving recruited recruitment Registered remained reported resolved RT-PCR Sample size SARS-CoV-2 RT-PCR secondary outcome severity severity of symptom shown Standard standard care status Study protocol supplementary material Symptom symptomatic syrup the patient time Trial Version Viral viral clearance website
[DOI] 10.1186/s13063-021-05081-3 PMC 바로가기 [Article Type] Letter

Can Zn Be a Critical Element in COVID-19 Treatment?

Zn이 COVID-19 치료에서 중요한 요소가 될 수 있습니까?

Review

Published on 2021-02-012022-09-11
Journal: Biological trace element research [Category] 치료제,

Homeopathy for Covid-19 in Primary Care: A structured summary of a study protocol for a randomized controlled trial

일차 진료에서 Covid-19에 대한 동종 요법: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-02-012022-08-31
Journal: Trials [Category] MERS, 임상, 치료제,

[키워드] 1:1 6 hour 6 hours acute respiratory syndrome Adverse adverse events alcohol alternative hypothesis appearance blinded Blinding block randomization bottle Brazil changed changes chest pain clinical trial cough COVID-19 defined dissemination dose double-blind Effectiveness elapsed element emergency services Fever followed by headache Home isolation homeopathic medicine homeopathic medicines Homeopathy hospitalizations identity Influenza Influenza-like symptoms Informed consent investigators measure medication Medicine Medicines Mild mild case mild cases muscle aches network null hypothesis number objective Older outcome Pain participant performed Placebo placebo-controlled positive RT-PCR primary care primary endpoint Primary Health Care protocol randomisation randomised Randomized Randomized controlled trial Randomized Controlled Trial protocol recorded Recovery time recruitment Registered required respiratory Sample size SARS-CoV-2 secondary Severe acute respiratory syndrome shakes sore throat statistician status study medication Study protocol submitted supplementary material Symptom Telemedicine Time to recovery tiredness treatment group Trial two group two groups Unified Health System university website without symptoms
[DOI] 10.1186/s13063-021-05071-5 PMC 바로가기 [Article Type] Letter

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

18~59세의 건강한 성인을 대상으로 한 비활성화된 SARS-CoV-2 백신의 안전성, 내약성 및 면역원성: 무작위 배정, 이중 맹검, 위약 대조, 1/2상 임상 시험

Clinical Trial

Published on 2021-02-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단,

[키워드] 1:1 acute respiratory syndrome Adverse reaction allergic assigned axillary temperature Beijing Block randomisation Cell chamber China Chinese clinical trial Cohort cohorts Community Corning CoronaVac coronavirus COVID-19 COVID-19 pandemic development diluent dose dose-escalating manner double-blind Efficacy Endpoint enrolled FIVE healthy High-dose hydroxide immunogenic inactivated Inactivated vaccine incidence Infection injection investigated investigators Jiangsu Laboratory live SARS-CoV-2 low dose low-dose morbidity and mortality neutralising antibody nine outcome participant per-protocol population phase 1 trial phase 2 trial Phase 3 trials Placebo placebo-controlled produced Program randomisation randomised Randomly receive recruited Registered Safety safety population SARS-CoV-2 SARS-CoV-2 vaccine Science separated Seroconversion seroconversion rate Seven Sinovac Life Sciences study drug suggested Taking technology the placebo group Tolerability treatment allocation Trial vaccination vaccination schedule Vaccine was done were excluded were given
[DOI] 10.1016/S1473-3099(20)30843-4 PMC 바로가기 [Article Type] Clinical Trial

High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL)

COVID-19 환자의 합병증을 예방하기 위한 고용량 비타민 D 대 위약: 무작위 대조 시험(CARED-TRIAL)을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-02-012022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 24 hour 24 hours Admission age allergy ambient and vitamin D anticonvulsants assessment Asthma Blinding block Blood body mass body mass index breathing ambient air calcium cardiovascular cardiovascular disease carried charge childbearing childbearing age cholecalciferol chronic Chronic kidney disease clinical clinical complications clinical outcomes comparator Complete Complication computer-generated Contact COPD coronary artery bypass grafting country COVID-19 COVID-19 patient COVID-19 patients criteria current death diabete diabetes discharge discretion disease dissemination dose double-blind Effect element enrolled evaluate exclusion exclusion criteria failure first stage FIVE gel Gender grafting Haemodialysis High dose history hospital Hospital admission hospital discharge Hospitalization hypercalcemia hypertension IMPROVE include inclusion criteria Infection Informed consent initiated Intervention invasive invasive or non-invasive ventilation investigator investigator-initiated investigators Kidney disease Life expectancy liver malabsorption management matching placebo mechanical ventilation medication moderate multicentre Myocardial infarction Non-invasive non-invasive ventilation number objective occur Occurrence oral cholecalciferol oral intake Organ failure outcome oxygen oxygen saturation Oxygenation packaged pandemic PaO participant Patient patients performed Pharmacist pharmacological physiological effects Placebo placebo-controlled clinical trial Pneumonia Pragmatic Prevent Primary outcome protocol pulse oximetry random randomised randomised controlled trial randomization randomization ratio Randomized recorded recruited recruitment Registered reported Requirement researcher respiratory Respiratory outcome respiratory outcomes risk routine clinical practice RT-PCR Sample size sarcoidosis SARS-CoV-2 Sepsis sequence sequential design serum calcium Seven stages Standard status stratified study drug study medication Study protocol subject supplementary material total sample size Treatment Trial Trial registration Two-arm valve replacement variable Vitamin D Vitamin D supplementation was used website
[DOI] 10.1186/s13063-021-05073-3 PMC 바로가기 [Article Type] Letter

Mouse Genome Database (MGD): Knowledgebase for mouse–human comparative biology

마우스 게놈 데이터베이스(MGD): 마우스-인간 비교 생물학을 위한 지식 기반

Comparative Study

Published on 2021-01-082022-09-10
Journal: Nucleic Acids Research [Category] MERS, 변종, 유전자 메커니즘,

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hour 24 hours Activation activities acute lung injury addition adjusted Administered administration allergy Antibiotics anticipated anticoagulation arterial Arterial hypertension Basel Blinding BMI Brazil Breast Breast feeding breathing ambient air C-reactive protein C1 esterase inhibitor cardiovascular disease Caregivers changes in Chest Child-Pugh score chronic chronic pulmonary disease chronic renal disease cirrhosis class clinical Clinical improvement clinical trial comparator comparator Patients complement complement system completion conducted Conestat alfa Contact contact activation system contraindication control group Corticosteroids COVID-19 COVID-19 patient CT scan death defined discharge disease disease severity dissemination drug Duration Efficacy and safety element eligibility enrolment evidence of experimental arm family members FIVE followed by history hospital Hospitalization hospitalized patient hypertension ICU IL-6 inhibitor IL-6R improvement Incapacity include inclusion criteria individual Infection inflammatory cascade inflammatory cascades inflammatory proteins inhibitor Interactive Web Response System interim analysis Intravenous injection invasive invasive or non-invasive ventilation investigator-initiated investigators kallikrein kinin system laboratory parameter Liver cirrhosis Local Lung injury mechanical ventilation non-invasive ventilation not blinded number obesity objective Open-label open-label trial Ordinal Scale outcome outcome assessor outcome assessors oxygen oxygen saturation pandemic PaO parallel-group participant Participants Participation Patient performed Pregnancy primary endpoint progression proportion protocol pulmonary disease pulmonary involvement randomised randomization Randomized randomized trial receive recombinant recruited recruitment Registered Remdesivir renal renal disease required risk factor Sample size SARS-COV-2 infection SARS-CoV-2 pandemic scale screened secondary Secondary outcomes severe COVID-19 severe SARS-CoV-2 Standard of care status Study protocol subject supplemental oxygen supplementary material suspicion Switzerland Symptom the SARS-CoV-2 the WHO their family members Tocilizumab Treatment treatment arm Trial Two interim analyses Two interim analysis virological clearance website WHO WHO ordinal scale with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter

Commonalities Between COVID-19 and Radiation Injury

COVID-19와 방사선 상해의 공통점

Review

Published on 2021-01-012022-09-11
Journal: Radiation research [Category] 바이오마커, 비임상, 임상,

[키워드] accelerate acute radiation syndrome acute respiratory distress acute respiratory distress syndrome Alter Anti-inflammatory approach approaches ARDS Asymptomatic Biomarker breath cardiovascular damage change chills complex component condition cough COVID-19 cytokine Cytokine storm discrimination disease effort etiology exposure to extreme extremities Fever Health Healthcare provider healthcare providers help High dose homeostasis hypoxia identify include infected individuals Intersection investigator investigators loss of taste loss of taste and smell management marker mechanism Medical conditions medical countermeasure Medical countermeasures Mild symptom mild symptoms Mortality Multiorgan occur pathology Patient pro-inflammatory molecule pro-inflammatory molecules public health emergency Radiation radiation biology radiation exposure radiation injuries Research respiratory distress SARS-COV-2 infection SARS-CoV-2-infected individual Still Symptom syndrome Taste Treatment variety virus while
[DOI] 10.1667/RADE-20-00188.1 PMC 바로가기 [Article Type] Review